Literature DB >> 11238662

Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-10: a comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system.

J L Croxford1, M Feldmann, Y Chernajovsky, D Baker.   

Abstract

Experimental allergic encephalomyelitis (EAE) is a CNS autoimmune disease mediated by the action of CD4(+) T cells, macrophages, and proinflammatory cytokines. IL-10 is a cytokine shown to have many anti-inflammatory properties. Studies have shown both inhibition and exacerbation of EAE after systemic IL-10 protein administration. We have compared the inhibitory effect in EAE of Il10 gene delivery in the CNS. Fibroblasts transduced with retroviral vectors expressing IL-10 could inhibit EAE. This was not associated with a prevention of cellular recruitment but an alteration in their phenotype, notably an increase in the numbers of CD8(+) T and B cells. In marked contrast, CNS delivery of adenovirus coding for mouse IL-10 or IL-10 protein performed over a wide dose range failed to inhibit disease, despite producing similar or greater amounts of IL-10 protein. Thus the action of IL-10 may differ depending on the local cytokine microenvironment produced by the gene-secreting cell types.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238662     DOI: 10.4049/jimmunol.166.6.4124

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

Review 1.  Molecular Mechanisms of the Action of Vitamin A in Th17/Treg Axis in Multiple Sclerosis.

Authors:  Mina Abdolahi; Parvaneh Yavari; Niyaz Mohammadzadeh Honarvar; Sama Bitarafan; Maryam Mahmoudi; Ali Akbar Saboor-Yaraghi
Journal:  J Mol Neurosci       Date:  2015-08-30       Impact factor: 3.444

2.  Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design.

Authors:  Mitchell R Emerson; Ryan J Gallagher; Janet G Marquis; Steven M LeVine
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

Review 3.  Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis.

Authors:  Monica K Mann; Avijit Ray; Sreemanti Basu; Christopher L Karp; Bonnie N Dittel
Journal:  Autoimmunity       Date:  2012-04-19       Impact factor: 2.815

4.  Interleukin-10 plays a crucial role in suppression of experimental autoimmune encephalomyelitis by Bowman-Birk inhibitor.

Authors:  Hong Dai; Bogoljub Ciric; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  J Neuroimmunol       Date:  2012-02-25       Impact factor: 3.478

Review 5.  Tissue engineering tools for modulation of the immune response.

Authors:  Ryan M Boehler; John G Graham; Lonnie D Shea
Journal:  Biotechniques       Date:  2011-10       Impact factor: 1.993

6.  CNS-specific therapy for ongoing EAE by silencing IL-17 pathway in astrocytes.

Authors:  Yaping Yan; Xiaoli Ding; Ke Li; Bogoljub Ciric; Shuai Wu; Hui Xu; Bruno Gran; Abdolmohamad Rostami; Guang-Xian Zhang
Journal:  Mol Ther       Date:  2012-03-20       Impact factor: 11.454

Review 7.  Biologic agents in experimental autoimmune uveitis.

Authors:  Gian Paolo Giuliari; Ama Sadaka; David M Hinkle
Journal:  Int Ophthalmol       Date:  2013-03-14       Impact factor: 2.031

8.  Adult neural stem cells expressing IL-10 confer potent immunomodulation and remyelination in experimental autoimmune encephalitis.

Authors:  Jingxian Yang; Zhilong Jiang; Denise C Fitzgerald; Cungen Ma; Shuo Yu; Hongmei Li; Zhao Zhao; Yonghai Li; Bogoljub Ciric; Mark Curtis; Abdolmohamad Rostami; Guang-Xian Zhang
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

9.  Prevention of experimental autoimmune encephalomyelitis in DA rats by grafting primary skin fibroblasts engineered to express transforming growth factor-beta1.

Authors:  T Zargarova; O Kulakova; V Prassolov; T Zharmukhamedova; V Tsyganova; V Turobov; D Ivanov; M Parfenov; M Sudomoina; Y Chernajovsky; O Favorova
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

10.  Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212.

Authors:  J Ludovic Croxford; Stephen D Miller
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.